Marshall Wace
ATYR

Marshall Wace’s aTyr Pharma ATYR Stock Holding History

Marshall Wace’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$108K Buy
+138,118
New +$117K ﹤0.01% 2883
2025
Q3 		– Sell
-511,412
Closed -$2.59M – 3510
2025
Q2 		$2.59M Sell
511,412
-327,040
-39% -$1.29M ﹤0.01% 1452
2025
Q1 		$2.53M Buy
+838,452
New +$3.06M ﹤0.01% 1366
2024
Q4 		– Sell
-14,031
Closed -$24.7K – 3084
2024
Q3 		$24.7K Buy
+14,031
New +$25.5K ﹤0.01% 2426
2024
Q2 		– Sell
-158,619
Closed -$309K – 3053
2024
Q1 		$309K Buy
+158,619
New +$277K ﹤0.01% 2098
2023
Q2 		– Sell
-10,947
Closed -$23K – 3047
2023
Q1 		$23K Sell
10,947
-129,349
-92% -$283K ﹤0.01% 2569
2022
Q4 		$307K Sell
140,296
-35,614
-20% -$84K ﹤0.01% 2561
2022
Q3 		$527K Buy
175,910
+16,503
+10% +$55.3K ﹤0.01% 2699
2022
Q2 		$450K Sell
159,407
-43,600
-21% -$158K ﹤0.01% 2837
2022
Q1 		$1.09M Sell
203,007
-47,389
-19% -$269K ﹤0.01% 2417
2021
Q4 		$1.87M Buy
250,396
+207,390
+482% +$1.73M ﹤0.01% 2081
2021
Q3 		$390K Buy
+43,006
New +$257K ﹤0.01% 2520

Other funds holding ATYR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Marshall Wace's ATYR Position: Q1 2026 in Review

Marshall Wace opened a new position in aTyr Pharma (ATYR) in Q1 2026: 138,118 shares worth $108K. The stake represents ﹤0.01% of the portfolio and ranks #2883 among its holdings. This is a return to the name: Marshall Wace previously reported a position in ATYR as recently as Q2 2025.

Marshall Wace first reported a position in ATYR in Q3 2021 and has held it in 12 quarters since. The position peaked at $2.59M in Q2 2025. 111 funds tracked by Wall St. Rank hold ATYR as of Q1 2026.

  • Marshall Wace held 138,118 shares of aTyr Pharma worth $108K as of Q1 2026.
  • aTyr Pharma was a new Marshall Wace position in Q1 2026.
  • aTyr Pharma made up ﹤0.01% of Marshall Wace's portfolio in Q1 2026, its #2883 holding.
  • Marshall Wace first reported a position in aTyr Pharma in Q3 2021 and has held it in 12 quarters since.
  • Marshall Wace's aTyr Pharma position peaked at $2.59M in Q2 2025.
  • 111 funds tracked by Wall St. Rank held aTyr Pharma as of Q1 2026.

Based on Marshall Wace's 13F filing for Q1 2026, filed 15 May 2026.